Clinical Data ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data pharminent June 9, 2026
Regulatory ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval pharminent June 9, 2026
Commercial ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option pharminent June 8, 2026
Clinical Data ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction pharminent June 8, 2026
Commercial Lilly and Novo face off at ADA 2026 as others seek to compete in obesity pharminent June 5, 2026
Clinical Data Kailera’s three-pronged obesity shot shows promise in early trial pharminent May 27, 2026
Clinical Data Lilly’s triple agonist shows bariatric surgery-like weight loss results pharminent May 21, 2026
Clinical Data ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term pharminent May 15, 2026
Clinical Data ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition pharminent May 13, 2026
Clinical Data Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching pharminent May 13, 2026
Clinical Data Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial pharminent May 13, 2026
Policy / Pricing What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge pharminent May 11, 2026
Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market pharminent May 8, 2026
Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales pharminent May 6, 2026
Commercial Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth pharminent April 30, 2026
Clinical Data Survodutide delivers 16.6% weight loss in major phase 3 obesity trial pharminent April 30, 2026
Commercial Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’ pharminent April 29, 2026
Clinical Data Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3 pharminent April 28, 2026
Market Access CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage pharminent April 23, 2026
Pipeline Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’ pharminent April 23, 2026
